NCT03251690View on ClinicalTrials.gov

Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression

NACompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Anti-Retroviral AgentsEfavirenzHIV-1-infectionSustained Virologic ResponseDyslipidemiasRilpivirine
Interventions
DRUG

Tenofovir/Emtricitabine/Rilpivirine

Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression

DRUG

Tenofovir/Emtricitabine/Efavirenz

as a active comparator

All Listed Sponsors
lead

Mahidol University

OTHER

NCT03251690 - Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression | Biotech Hunter | Biotech Hunter